# DARZALEX (daratumumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/daratumumab

> The next catalyst for DARZALEX (daratumumab), sponsored by JOHNSON & JOHNSON (JNJ), is its topline data readout, Feb to May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | DARZALEX (daratumumab) |
| Codes | JNJ-54767414 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Multiple Myeloma](https://sec-api.dev/indications/multiple-myeloma), Amyloidosis |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### June 29, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20200629, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### August 20, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20200820, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### March 4, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20220304, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### January 19, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### July 31, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20240731, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### Nov 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-08-07, last confirmed 2025-08-07.
- SEC Form 8-K (accession 0001434265-25-000063): "In November 2024, J&J also submitted a sBLA to the FDA seeking approval for daratumumab SC in this indication in the U.S. Please consult the European Summary of Product Characteristics for DARZALEX and DARZALEX SC and the U.S. Prescribing Information for DARZALEX and DARZALEX FASPRO for the labeled indication and safety information." https://www.sec.gov/Archives/edgar/data/1434265/000143426525000063/gmab-20250630.htm

### January 23, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250123, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### April 10, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761036 SUPPL-54 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22

### May 2025: FDA advisory committee meeting

- Status: completed, positive. Date confidence: month.
- First seen 2025-08-05, last confirmed 2025-08-05.
- SEC Form 10-Q (accession 0001159036-25-000034): "•In May 2025, Janssen announced the U.S. Food and Drug Administration ("FDA") Oncologic Drug Advisory Committee voted in favor of the benefit-risk profile of DARZALEX FASPRO for the treatment of adult patients with high risk smoldering multiple myeloma." https://www.sec.gov/Archives/edgar/data/1159036/000115903625000034/halo-20250630.htm

### August 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05083169 (A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05083169

### February 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Amyloidosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05250973 (A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05250973

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT04133636

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT04133636

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05455320

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05455320

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05438043

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05438043

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06577025

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07665450

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06577025

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07665450

## Same indication

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) (GILD)
- [Arlocabtagene autoleucel](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) (BMY)
- [BB2121](https://sec-api.dev/pdufa/bb2121) (BMY)
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin) (GSK)
- [Cemsidomide](https://sec-api.dev/pdufa/cemsidomide) (CCCC)
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel) (JNJ)
- [Empliciti (elotuzumab)](https://sec-api.dev/pdufa/elotuzumab) (BMY)
- [Elrexfio (elranatamab)](https://sec-api.dev/pdufa/elranatamab) (PFE)
- [Etentamig](https://sec-api.dev/pdufa/etentamig) (ABBV)
- [Zenbexus (iberdomide hydrochloride)](https://sec-api.dev/pdufa/iberdomide) (BMY)
- [ABECMA (idecabtagene vicleucel)](https://sec-api.dev/pdufa/idecabtagene-vicleucel) (BMY)
- [Igi, 10%](https://sec-api.dev/pdufa/igi-10) (TAK)
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322) (JNJ)
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide) (JNJ)
- [PHE885](https://sec-api.dev/pdufa/phe885) (NVS)
- [Pomalyst (pomalidomide)](https://sec-api.dev/pdufa/pomalidomide) (BMY)
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig) (JNJ)
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab) (JNJ)
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab) (JNJ)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax) (ABBV)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [July 2027](https://sec-api.dev/fda-calendar/2027-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/daratumumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DARZALEX (daratumumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/daratumumab

```bibtex
@misc{secapidev_pdufa_daratumumab_20261116,
  title        = {DARZALEX (daratumumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/daratumumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_daratumumab_20261116","title":"DARZALEX (daratumumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/daratumumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
